MedTrace Logo

Galantamine in the Treatment of Post-Traumatic Headache

NCT00219869 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2005-09-22

No results posted yet for this study

Summary

Most patients with CPTH present with additional major cognitive, behavioral and somatic problems. Most drugs used currently have a negative influence on cognition. Therefore, treatment strategies addressing both the headache and cognitive disturbances in patients with CPTH are necessary. (CPTH; Chronic Post Traumatic Headache).

Conditions

  • Post-Traumatic Headache
  • Head Trauma,Closed
  • Retention Disorders,Cognitive

Interventions

DRUG

Galantamine

Sponsors & Collaborators

  • Ortho-McNeil Neurologics, Inc.

    collaborator INDUSTRY

  • Rapoport, Alan, M.D.

    lead INDIV

Principal Investigators

  • Alan Rapoport, MD · The New England Center for Headache

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-07-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219869 on ClinicalTrials.gov